Clinical trials: Tace
HCC
Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
This study will evaluate the efficacy and safety of TACE combined with atezolizumab + bevacizumab in the treatment of unresectable hepatocellular carcinoma, and the treatment patterns of the combination regimen
- Trial name
- CHANCE023 (NCT06024252)
- Testing
- TACE
- Volunteers
- 200 people
- Sponsor
- Zhongda Hospital
Hepatocarcinoma
Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC
This is a prospective, single-center, phase II study，to evaluate the efficacy and safety of icariin soft capsules combined with TACE as adjuvant therapy in hepatocellular carcinoma (HCC) patients at high risk of recurrence after…
- Trial name
- NCT06900478
- Testing
- Icariin Soft Capsules+TACE
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Hua Li
Unresectable Hepatocellular Carcinoma
A Clinical Study of Precision TACE (P-TACE) With Surefire
The purpose of this research study is to learn about 2 types of FDA-approved catheters used in angiographic (X-ray of blood vessels, with radiopaque substance) procedures like DEB-TACE treatment.
- Trial name
- NCT03345225
- Testing
- SureFire Infusion System, Standard Endhole Microcatheter
- Where
- United States
- Sponsor
- University of Miami
Hepatocellular Carcinoma
TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma
The purpose of this study is to determine if TACE plus Recombinant Human Adenovirus Type 5 Injection will improve outcome in patients with advanced hepatocellular carcinoma (HCC) not amenable to surgery or local ablative therapy.
- Trial name
- NCT01869088
- Testing
- Recombinant Human Adenovirus Type 5 Injection, Transartery Chemoembolization
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Sun Yat-sen University
HCC - Hepatocellular Carcinoma, TACE(Transcatheter Arterial Chemoembolization)
A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma
By comparing the diagnostic accuracy of spectral CT and conventional CT in evaluating treatment response efficacy after TACE, this study aims to investigate the diagnostic performance of spectral CT in assessing treatment…
- Conditions
- HCC - Hepatocellular Carcinoma, TACE(Transcatheter Arterial Chemoembolization), CT
- Trial name
- NCT07351669
- Where
- China
- Volunteers
- 121 people
- Sponsor
- Zhongda Hospital
Colorectal Cancer
TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer
The primary objective of this study is to evaluate the efficacy of Irinotecan Beads in combination with intravenous cetuximab versus intravenous irinotecan in combination with intravenous cetuximab in the treatment of patients…
- Trial name
- DEBIRITUX (NCT01060423)
- Testing
- Cetuximab, Irinotecan, Irinotecan eluting BEADS
- Where
- 13 sites in Germany
- Volunteers
- 8 people
- Sponsor
- Hans-Joachim Schmoll, MD
HepatoCellular Carcinoma
Comparison of SBRTand Repeat TACE for HCC
Comparison of Stereotactic Body Radiation Therapy (SBRT) and repeated transarterial chemoembolization (TACE) for Hepatocellular Carcinoma (HCC)as a Local Salvage Treatment after first incomplete TACE
- Trial name
- STH (NCT03326375)
- Testing
- SBRT
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Gangneung Asan Hospital
Hepatocellular Carcinoma
Multi-Detector CT Angiography With 3D Reconstruction Versus Digital Subtraction Angiography
This study aims to investigate the feasibility and accuracy of Multi-Detector CT angiography acquired before Trans-arterial Chemo-embolization (TACE) in detecting Hepato-cellular carcinoma feeding vessels compared to DSA…
- Trial name
- NCT05304572
- Testing
- Multi-Detector CT angiography, Trans-arterial chemoembolization and DSA
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Assiut University
Advanced Hepatocellular Carcinoma (HCC)
Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma
This study is to evaluate the feasibility and safety of personalized tumor neoantigen mRNA therapy iNeo-Vac-R01 combined with PD-1 monoclonal antibody, anti-VEGFR monoclonal antibody and TACE regimen for the treatment of patients…
- Trial name
- NCT06995105
- Testing
- TACE, Sintilimab combined with Bevacizumab, individualized anti-tumor new antigen iNeo-Vac-R01 injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
Hepatocellular Carcinoma, Unresectable
Songyou Granule and Transarterial Chemoembolization for Hepatocellular Carcinoma
Songyou Granule is a mixture of 6 herbs. Vitro and vivo studies showed that Songyou Granule can inhibit HCC cells grow, and HCC metastasis.
- Trial name
- NCT00805896
- Testing
- Songyou
- Where
- 2 sites in China
- Volunteers
- 260 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02)
The objective of this study is to evaluate the efficacy and safety of TACE combined with Sintilimab plus bevacizumab biosimilar in patients with advanced hepatocellular carcinoma as first-line therapy.
- Trial name
- NCT04954794
- Testing
- Sintilimab, TACE
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Fudan University
Transarterial Chemoembolization, Hepatocellular Carcinoma
TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC
Purpose：explore the effectiveness and safety of transarterial chemoembolization (TACE) plus Hepatic Arterial Infusion Chemotherapy (HAIC) with oxaliplatin and raltitrexed for Barcelona stage C hepatocellular carcinoma (HCC)
- Trial name
- OXRI (NCT04597970)
- Testing
- cTACE-HAIC
- Volunteers
- 66 people
- Sponsor
- Peking University Cancer Hospital & Institute
HCC
A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence
For patients with early- to mid-stage hepatocellular carcinoma (HCC), the five-year postoperative recurrence and metastasis rate remains as high as 70%, significantly impacting patient prognosis.Therefore, perioperative therapy…
- Trial name
- NCT07009470
- Testing
- Finotonlimab (an anti-PD-1 monoclonal antibody) and Anbeizhu (a bevacizumab biosimilar), TACE
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Tongji Hospital
HCC
Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma.
Hepatocellular carcinoma (HCC) is a major health problem worldwide, and most cases are inoperable because of late presentation and underlying cirrhosis.
- Trial name
- NCT02715492
- Testing
- LMWH, TACE
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Sherief Abd-Elsalam
Hepatocellular Carcinoma
Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCC
TACE is considered the standard treatment for unresectable HCC on the basis of the fact that there are no alternative to curative procedures.But the optimal combined regimen is still unclear.
- Trial name
- NCT01229839
- Testing
- Embolization, Infusion of anticancer agent, Infusion of mixture of anticancer agent and lipiodol
- Where
- China
- Volunteers
- 668 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Hepatocellular
Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma
The purpose of this study is to determine whether compared with arsenic trioxide TACE alone, arsenic trioxide TACE and intravenous administration could further prolong the overall survival.
- Trial name
- ACTION (NCT01861912)
- Testing
- Arsenic trioxide TACE, Arsenic trioxide intravenous infusion, lipiodol
- Volunteers
- 258 people
- Sponsor
- Guangdong Provincial People's Hospital
Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization
CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC
This retrospective multicenter study aims to evaluate whether radiographic microvascular invasion (MVI) status can predict treatment response in patients with intermediate-stage hepatocellular carcinoma (HCC) receiving…
- Conditions
- Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization, Microvascular Invasion (MVI), Tyrosine Kinase Inhibitors
- Trial name
- NCT07449065
- Testing
- TKI, TACE
- Where
- China
- Volunteers
- 324 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma
A Study to Evaluate Autologous CIK Cells in Patients With Hepatocellular Carcinoma After TACE, PEIT or RFA
A Phase I/II, Open Label Study to Evaluate the Safety and Efficacy of Autologous Cytokine-Induced Killer (CIK) Cell for Patients with Hepatocellular Carcinoma (HCC) after Transarterial Chemoembolization (TACE), Percutaneous…
- Trial name
- NCT03124498
- Testing
- CIK Cell
- Volunteers
- 55 people
- Sponsor
- Chuan An Biotechnology Co., Ltd.
Hepatocellular Carcinoma
The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study
Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However, any treatment guidelines do not specify the criteria for repeating TACE.
- Trial name
- NCT05121571
- Testing
- HAIC, Sorafenib
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Sun Yat-sen University
Primary Hepatocellular Carcinoma
Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy
Although liver resection, liver transplantation, a-interferon, Transarterial Chemo Embolization (TACE), percutaneous ethanol injection (PEI), Percutaneous microwave coagulation therapy (PMCT), Radiofrequency ablation (RFA)…
- Trial name
- DC-TC (NCT01828762)
- Testing
- DC-TC+GM-CSF
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Shanghai AbelZeta Ltd.